Faecal Microbiota Transplantation from Patients with Depression Into Rats Modulates Mood-Related Behaviour

Suzette Sørensen (✉ suzette.soerensen@m.dk)

Aalborg University

Julie Knudsen

Aalborg University

Thomas Michaelsen

Aalborg University

Caspar Bundgaard-Nielsen

Aalborg University

René Ernst Nielsen

Aalborg University Hospital

Simon Hjerrild

Aarhus University

Peter Leutscher

Aalborg University

Gregers Wegener

Aarhus University

Research Article

Keywords: microbiota, major depressive disorder (MDD), faecal microbiota transplantation (FMT), Ruminococcaceae, Lachnospira genus

Posted Date: July 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-671170/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Differences in gut microbiota composition have been observed in patients with major depressive disorder (MDD) compared to healthy individuals. Here, we investigated if faecal microbiota transplantation (FMT) from MDD patients into rats, could induce a depressive-like phenotype. We performed FMT from patients with MDD (FMT-MDD) and healthy individuals (FMT-Healthy) into male Flinders Sensitive Line (FSL) and Flinders Resistant Line (FRL) rats and assessed depressive-like behaviour. No behavioural differences were observed in the FSL rats. In FRL rats, the FMT-Healthy group displayed significantly lower depressive-like behaviour than the FMT-MDD group. However, there was no difference in behaviour between FMT-MDD FRL rats and negative controls, indicating that FMT-Healthy FRL rats received beneficial bacteria. We additionally found different taxa between the FMT-MDD and the FMT-Healthy FRL rats, which could be traced to the donors. Four taxa, three belonging to *Ruminococcaceae* and the *Lachnospira* genus, were significantly elevated in relative abundance in FMT-MDD rats, while *Coprococcus* was depleted. In this study, the FMT-MDD group was different from the FMT-Healthy group based on behaviour and intestinal taxa.

Introduction

An association between an altered gut microbiota composition and major depressive disorder (MDD) has been explored in several studies (1–18). Changes in specific bacterial taxa have been investigated in patients with MDD in comparison to healthy control groups. Here, most studies found that the patient and control groups could be separated based on either α - or β -diversity, as well as an increased relative abundance of the genera *Eggerthella*, *Atopobium* and *Bifidobacteria*, and decreased *Faecalibacterium* in patients with MDD (19). Differences in the structural composition of the gut microbiota have primarily been explored, but the functional effects of the bacteria present in the intestinal system have not been explored clinically. It is therefore difficult to deduce, if the observed changes in the microbiota are involved in a pathogenesis of MDD.

Different mechanisms potentially involved in the development of MDD have been hypothesized to be influenced by the gut microbiota. Intestinal bacteria may affect the brain by priming the immune system in the gut and subsequently in the body (20, 21), or by metabolizing intestinal tryptophan to serotonin, providing the host with up to 70% of the body's total serotonin for neurotransmission (22). On the other hand, the brain affects the gut by regulating gastrointestinal motility and secretion of hormones, in close cooperation with the enteric nervous system (23). This bidirectional communication between the gut and the brain is termed the gut-brain axis (24). This axis has been implicated in the pathogenesis and development of neuropsychiatric disorders, including MDD (25). Different gut microbial species are known to produce metabolites that may result in mental and emotional changes (26). Studies have supported this concept, as supplementation with probiotics, which produce metabolites such as the short chain-fatty acids (SCFAs), to patients with MDD resulted in a reduction of depressive symptoms (27, 28). It has furthermore been hypothesized that depressive-like behaviour in animal models arises from harmful bacteria-produced metabolites, such as lipopolysaccharides, entering the bloodstream (29–31).

Studies have observed reduced intestinal tight junction proteins in animals with gut microbiota alterations, which may increase barrier permeability, allowing the translocation of potentially harmful bacterial metabolites which cannot normally pass this barrier (32, 33). This phenomenon, termed 'leaky gut', has been hypothesized to be involved in the pathogenesis and development of MDD (34, 35), as it is speculated that this allows transfer of metabolites leading to increased inflammation (36).

Proof-of-concept studies have explored whether the gut microbiota of patients with MDD is involved in the pathogenesis and development of MDD. In four studies, faecal microbiota transplantation (FMT) was performed from patients with MDD into recipient animals (3, 5, 37, 38). Each study observed behavioural alteration in the animals receiving FMT from patients with MDD compared to control animals receiving FMT from healthy individuals. The alterations were plausibly linked to the transplantation of distinct bacteria with specific neuropathophysiological features. Although these studies found behavioural differences between animals receiving FMT from patients with MDD compared to healthy individuals, the applied animal models may have imposed behavioural differences prior to FMT. This necessitates the inclusion of additional control groups. Additionally, no previous study have attempted to reverse depressive-like behaviour by performing FMT from healthy individuals into an animal model of depression.

The current work aimed to assess the behavioural changes in a rat model of depression upon transplantation of faeces from either antidepressant treatment-naïve patients with MDD or healthy individuals. Moreover, we aimed to characterize the post-transplant gut microbiota in the recipient animals by 16S rRNA gene sequencing to elucidate if behavioural changes were associated with a shift in the gut community. Finally, we wanted to explore if there were any induced differences between the groups in tight junction protein expression in the caecum.

Methods

Human donors

Faecal samples were obtained from five antidepressant-naïve female patients recently diagnosed with first ever unipolar depression according to International Classification of Diseases, 10th Edition (ICD-10) criteria by a psychiatrist, as well as from five healthy female individuals. They were between 18 and 24 years of age, while the healthy individuals were between 23 and 30 years of age. The faecal material was obtained in continuation of a clinical study, which was conducted in accordance with the Helsinki Declaration. This study was approved by the Danish Ethical Committee (ID number: N-20170056). All participants gave informed consent to the use and application of their faecal samples in this study. The personal data collected in the project was registered in the processing activities of research in North Region of Denmark in compliance with EU GDPR article 30. Results from the clinical study will be published separately from the animal study.

Animal recipients

Healthy 6–8-week-old (49.18 ± 4.86 days) male Flinders Sensitive Line (FSL) and Flinders Resistant Line (FRL) rats were procured from the breeding facility of the Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Denmark. The FSL rat is a validated animal model of depression when behaviour is compared to the control FRL rat (39–41). Animals were cohoused in pairs according to strain and birthmother in standard cages with access to *ad libitum* standard chow (#1324 Altromin, Brogaarden ApS, Lyngby, Denmark) and water. The facility had a 12h light/dark cycle (lights on at 8 AM), a temperature of $20 \pm 2^\circ\text{C}$ and a relative humidity of $60 \pm 5\%$. Animals were acclimatised to their new living conditions for one week before initiating the transplantation process. All animal experiments were conducted at the Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, approved by the European Union Council Directive on animal experimentation (ID Number: 2016-15-0201-01105) and conducted according to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (42). All animal experiments were performed in accordance with guidelines on ethical conduct in animal research, including the 3 R's (replacement, reduction and refinement) (43). A total of 10 animals were used per group, as this sample size is necessary to determine a large enough effect size (44).

Faecal microbiota transplantation

Faecal samples from either the five patients with MDD or the five healthy individuals was pooled together for a total of 91 grams. The pooled faecal sample was homogenised with 500 mL phosphate buffered saline and added 50 mL of glycerol to create a faecal solution. Rats were divided into nine groups ($n = 10$ per group). This sample size was chosen as this is the minimum requirement of animals to be able to determine significant differences between groups in the forced swim test (45, 46). This was also used as the primary outcome measure. Five groups of rats received faecal transplants from human donors as follows: 1) Patients with MDD (FMT-MDD, FSL $n = 10$, FRL $n = 10$). 2) Patients with MDD, then subsequently administered sertraline hydrochloride (Carbosynth®) at a dose of 16.7mg/kg/day at a minimum of three hours after FMT by oral gavage (FMT-MDD-Ser, FRL $n = 10$). 3) Healthy individuals (FMT-Healthy, FSL $n = 10$, FRL $n = 10$). Sertraline hydrochloride was administered chronically at a dose of 16.7mg/kg/day, as the FSL rat only responds to chronic antidepressant treatment (47–49) and this dose resembles clinically relevant dosages (50).

Two additional groups did not receive FMT from humans and served as controls. In one of the two groups, faecal samples were collected directly from the co-housed animals, pooled and homogenized to create an animal faecal solution identical in concentration to the human faecal solutions, which was administered back into the rats (CON-AUTO, FSL $n = 10$, FRL $n = 10$). The second control group received demineralised water in a volume identical to the volumes administered during the FMT procedures (CON-H2O, FSL $n = 10$, FRL $n = 10$).

FMT was performed thrice weekly for a three week period by oral gavage in a volume corresponding to the recommended guidelines by the European Consensus Conference on FMT in clinical practice (51). This resulted in a faecal sample dosage of 0.42g/kg with a solution of 0.9 mL administered per FMT. The CON-H2O group was administered 0.9mL demineralised water thrice weekly for three weeks. Animals

were excluded from the study if they stopped gaining weight, or lost weight, during the three weeks FMT was performed.

Behavioural assessment of animals

Behavioural tests were performed two days after the last FMT in the order *open field test* – *rotarod test* – *training-session forced swim test*. The *testing-session forced swim test*, from which depressive-like behaviour was evaluated, was performed on the following day. Animals were moved into the behavioural facility one hour before initiating the experiments to acclimatise in a room with a red light of 35–45 lux. All test procedures were performed by the same experimenter specialized in animal behavioural assessment.

Forced swim test

A modified version of the forced swim test was employed. The modification included a six-minute forced swim training-session, 24 hours prior to the six-minute test-session (45, 46). Videos of the test sessions were then randomized and scored by an observer. Immobility, swimming and struggling behaviour were scored as the dominant behaviour displayed every five seconds and interpreted as passive coping (depressive-like), swimming or active escape (antidepressant) behaviour. The first five minutes of the test-session videos were analysed. One FRL rat from the FMT-Healthy group was not fully submerged into the water during placement in the cylinder and was thus excluded from the behavioural analysis.

Open field test

The open-field test was performed under white light of 35–45 lux as previously described to measure locomotor activity (52, 53). Movement trajectory was recorded for ten minutes using a camera positioned directly above the open field. Locomotor activity was analysed using the Noldus Ethovision XT v. 14 software (Wageningen, Netherlands). The open field test was used as a control to ensure that alterations in struggling, swimming or immobile behaviour in the forced swim test was not due to differences between groups in overall locomotor activity.

Rotarod Test

Animals were transferred directly from the open field test room to the rotarod test room with a dimmer light of 10–15 lux. Animals were individually placed on a spinning cylinder (Ugo Basile) specifically designed to rotate at increasingly higher speeds. The time-to-exhaustion was determined as the time passed until the rat fell off the rotating cylinder and measured to ensure that immobility in the forced swim test was not due to animal variations in energy output. The rotarod test was included as a control to ensure that differences in struggling, swimming or immobile behaviour in the forced swim test was not due to differences in endurance between groups.

Gene expression analysis

Gut tissue was collected from the animals to evaluate the expression of tight junction proteins in the caecum. Animals were euthanised by decapitation, the intestines dissected, and the base of the caecum was separated and placed in RNeasy Lysis Buffer (Qiagen) before long-term storage at -80°C. Total RNA was extracted using the RNeasy Tissue kit (Qiagen). RNA concentration was measured using the NanoDrop (ThermoFischer) and integrity was assessed using the Qubit™ RNA IQ kit (ThermoFischer). Gene expression levels of rat *Ocln* (occludin), *Cldn3* (claudin-3) and *Gapdh* (GAPDH) was measured using a two-step qRT-PCR approach. First, cDNA was produced using the Affinity Script qPCR cDNA Synthesis kit (Agilent) followed by qPCR with the Brilliant III SYBR® Green qPCR Master Mix (Agilent) according to manufacturer's recommendations. Primers were designed targeting rat *Ocln* (Fw-*ocln*: 5'-AACCGACTACACGACAGGTG-3' and Re-*ocln*: 5'-AGCCATGTACTCTTCGCTCTC-3'), *Cldn3* (Fw-*cld3*: 5'-GAATGGACAAAGACACCTCGC-3' and Re-*cldn3*: 5'-CCACTATGAGCCTTCTGGCTG-3') and *Gapdh* (Fw-*gapdh*: 5'-AGTGCCAGCCTCGTCTCATA-3' and Re-*gapdh*: 5'-GGTAACCAGGCGTCCGATAC-3'). Relative expression levels of *Ocln* and *Cldn3* were determined by the $\Delta\Delta C_t$ method against *Gapdh* expression.

16S rRNA gene sequencing

Faecal samples collected from rats before transplantation (pre-FMT) and after transplantation (post-FMT) were stored for a maximum of three hours on dry ice before long-term storage at -80°C. DNA was extracted from the human and rat faecal samples using the QIAamp PowerFecal Kit (Qiagen) as previously described (54). DNA concentration was determined by a Qubit 4 fluorometer (Thermo Fischer). Gene sequencing of the 16S rRNA gene was performed by DNAsense, Denmark, on a MiSeq (Illumina) (55) with primers 515F/806R targeting the hypervariable V4 region (56, 57) as previously described (58). To ensure the quality of sequencing, a 20% PhiX control library (Illumina, USA), a negative control (nuclease-free water), and a positive control (anaerobic digester system sample) were added before sequencing.

Bioinformatics and statistics

Data analysis was performed in R v. 3.6.0 through Rstudio v. 1.1.383 (<http://www.rstudio.com>) primarily using the packages ampvis2, tidyverse, and vegan. Forward and reverse reads were trimmed using Trimmomatic v0.32 (59) and merged using FLASH v1.2.7 (60). The data was then processed using the USEARCH amplicon workflow (61), implemented in QIIME (62). OTUs were clustered to 97% sequence identity and assigned taxonomy using the MiDAS database v.2.1.3 (63). Samples were rarefied to the lowest observed sequencing depth for richness and diversity estimates. Community richness was calculated using the observed number of unique OTUs and diversity was calculated using the Shannon index. β -diversity was examined using principal component analysis (PCA) on Hellinger transformed OTU abundances. To assess the statistical significance of the groupings in PCA, averages of each grouping levels were fitted to the ordination using the envfit function from the vegan package. To analyse differential abundance of OTUs between groups from pre-FMT to postFMT samples, the DESeq2 v.1.20.0 workflow was used (64). Distribution and variance of continuous data were analysed using Shapiro-Wilks test and Bartlett's test, respectively. Data was tested using either ANOVA followed by Tukeys post hoc test, or Kruskal-Wallis test followed by Dunn's post hoc test depending on normality and variance. For

statistical comparison of pre-FMT and post-FMT results, the Wilcoxon rank sum test was used. The Benjamin-Hochberg p-value correction was used to address multiple testing (65). An adjusted p-value < 0.05 was considered statistically significant. The bacterial sequencing data is freely available through the NCBI Sequence Read Archive under the ID number PRJNA741104.

Results

Faecal microbiota transplantation from humans into FRL rats can modulate the behavioural phenotype

The forced swim test was applied to evaluate whether FMT from patients with MDD could induce depressive-like behaviour in rats. A tendency of depressive-like behaviour was observed in the FMT-MDD group compared to the FMT-Healthy group with 19% higher average immobility ($p = 0.088$) and 32% lower average struggling times ($p = 0.013$) (Fig. 1A and 1B, respectively). Administration of sertraline resulted in a behavioural phenotype intermittently between the FMT-MDD and FMT-Healthy groups. However, the control groups, CON-AUTO and CON-H2O showed comparable immobility and struggling times to the FMT-MDD groups. This could imply that the transfer of faeces from healthy individuals imposed a beneficial effect on inherent depressive-like behaviour instead of an adverse impact from the faeces of depressed patients.

In contrast to the FRL rats, FSL rats did not display altered behaviour regardless of treatment (Fig. 1C and 1D). To ensure that the behaviour observed during the forced swim test was not caused by differences in locomotor activity or time-to-exhaustion, the animals also underwent the open field test and the rotarod test (*Supplementary Fig. 1A and 1B*, respectively). While there was no difference between the five FRL groups in total distance travelled in the open field test, there was a statistical difference between the FMT-Healthy and the CON-AUTO groups, with the CON-Auto group spending significantly more time on the Rotarod ($p = 0.015$).

Donor bacteria can be observed in faecal samples of recipient rats

We assessed whether the bacterial composition of the recipient rats was affected by the FMT. For this purpose, 16S rRNA gene sequencing was performed on faecal samples collected before and after transplantation. Human donor bacteria could be detected in FRL rats after transplantation, but only accounted for approx. 9.7 ± 1.5 SD % of the overall gut microbiota composition (Fig. 2).

This contribution was not sufficient to induce changes in α -diversity between pre- and post-treatment groups (*Supplementary Fig. 2*). Analyses of β -diversity, on the other hand, showed that post-treatment groups were significantly different from each other (*Supplementary Fig. 3*). The data, however, also showed that the FMT-MDD rats differed in gut microbiota composition compared to FMT-Healthy rats prior to the FMT procedure.

In addition, we assessed whether individual bacterial phylotypes were significantly different between the groups. In total, seventeen taxa were increased in relative abundance in FMT-MDD rats compared to FMT-healthy rats, and eight were decreased (Fig. 3A). Of these, five taxa could be traced to the donor material, but with significantly different fold changes depending on the donor group (Fig. 3B). The genus *Lachnospira* and three genera belonging to the *Ruminococcaceae* family were overrepresented in relative abundance in FMT-MDD rats, while the genus *Coproccoccus* was underrepresented.

FMT from humans induced altered intestinal tight junction gene expression

Induction of behavioural differences after transplantation may be caused by changes in local intestinal tight junction protein expression. To investigate this, we measured mRNA expression levels of the tight junction protein-coding genes, *ocln* and *cldn3* (Fig. 4). Surprisingly, there was a significantly higher relative gene expression of *cldn3* in FMT-MDD rats compared to FMT-Healthy and CON-H2O, indicating an upregulation of one of the tight junction proteins. Expression levels of *ocln* were not observed to be different between groups.

Discussion

We explored if a depressive-like phenotype was induced in rats by FMT from treatment-naïve patients with MDD compared to FMT from healthy individuals. Here, we observed that the FMT-MDD group displayed depressive-like behaviour compared to the FMT-Healthy group, but not compared to the control groups CON-Auto, or CON-H2O. While there were no significant changes in α - or β -diversity from pre-FMT to post-FMT, individual phylotypes were observed to be significantly different between FMT-MDD and FMT-Healthy, five of which could be traced to the donor material.

Behavioural phenotypes observed in this study are similar to previous reports despite animal model differences

The FMT-MDD group tended towards higher immobility and significantly less struggling in the forced swim test compared to the FMT-Healthy animals. This indicated that the microbiota from patients with MDD may be able to induce a depressive-like phenotype, as lack of struggling and increased immobility are interpreted as a display of a depressive phenotype (45). Furthermore, in our study, treatment with sertraline simultaneous with FMT from patients led to a trend towards a less depressive phenotype. However, the FMT-MDD group did not display less struggling than the control groups, suggesting that FMT from healthy individuals rather has an antidepressant-like effect, than FMT from patients with MDD resulting in a depressive-like phenotype. As a result, it was not possible to establish an association between the gut microbiota of patients with MDD and induced depressive-like behavior in FMT-recipient

rats, as this is not evident from the behavior in comparison to the CON-H2O group. Although the FMT-Healthy does appear to decrease depressive-like behavior in the FRL rat, this was not observed in the FSL rat. This suggests that should FMT from healthy individuals into FRL rats induce an antidepressant phenotype, this cannot be replicated in a genetic animal model of depression like the FSL rat.

Although previous studies did observe a depressive-like phenotype when comparing animals receiving FMT from patients with MDD to animals receiving FMT from healthy individuals (3, 5, 37), these studies did not involve control groups which did not receive FMT with human material. It can therefore be difficult to discern if the behavioural output from the animals arise from the FMT, or their inherent, natural behaviour. Additionally, their patients with MDD received active pharmacological treatment, whereby it can be suggested that the gut microbiota composition may have partly shifted away from a 'depressogenic' composition. On the other hand, one study has included an additional control group and contrarily to our study, they observed depressive-like behaviour in their animals receiving FMT from patients with MDD compared to the non-intervention control rat (38). This may be due to strain differences (Sprague-Dawley rats in their study, versus FSL/FRL rats in ours). It may also be due to differences in the animal model, as their rats were germ-free prior to transplantation, while our model did not include pre-treatment. However, all studies with FMT from patients with MDD compared to FMT from healthy individuals did observe significant behavioural differences between these two groups, despite apparent strain and animal model variations.

Bacterial metabolites may facilitate behavioural differences

Five OTUs were observed to be significantly altered in recipient FMT-MDD and FMT-Healthy animals, which could be traced to the donor material; three from the family *Ruminococcaceae* and one from the genus *Lachnospira* were enriched in FMT-MDD animals, while the genus *Coprococcus* was depleted, compared to the FMT-Healthy group. *Lachnospira* has not previously been reported enriched in neither patients diagnosed with MDD (1–18), nor in the previously performed studies of FMT (3, 5, 37), but the family *Lachnospiraceae* has been observed significantly altered in both clinical studies (1–3, 7, 9, 10, 16, 17, 66) and in one of the FMT studies (3). *Lachnospira* has furthermore been observed in serotonin transporter knockout rats with genetic serotonin transporter knockout receiving early life stress (67), a validated animal model of depression (68). This suggests that *Lachnospira* may promote behavioural changes through interactions with neurotransmitter systems, which is also one of the primary interactions in the gut-brain axis (25).

Low relative abundance of *Coprococcus* has previously been recognized in clinical assessments of the gut microbiota in patients with MDD (3, 10, 12, 18), and in mice subjected to social defeat stress, an animal model of depression (69). *Coprococcus* is a prominent producer of SCFAs (70), metabolites catalysed from undigestible, complex fibres. The severity of MDD has been positively associated with plasma SFCA concentration (71), and faecal SCFA content is reduced in clinical assessments of gut microbiota in patients with MDD (2, 3). This suggests that increased *Coprococcus* in the FMT-Healthy group may be the mediator of the antidepressant-like behaviour observed compared to FMT-MDD.

In this study, we were able to induce an antidepressant effect of FMT from healthy individuals compared to FMT from patients with MDD into FRL rats. Furthermore, this can be associated to the intestinal bacteria observed in the rat after FMT, which could be traced to the donor material. Furthermore, future studies should include additional control groups, as was done in this study, to be able to discern that FMT from patients with MDD is depressogenic or if rather FMT from healthy individuals can rescue an underlying depressive phenotype.

Limitations and strengths

The primary limitation in our study is the presence of a gut microbiota in recipient rats prior to FMT, reducing the colonization success of the donor material. Furthermore, the faecal material used for transplantation was pooled from five different individuals. In the bioinformatical processing, we used OTUs instead of amplicon sequence variants, which limits detection of bacteria at species level.

The strengths of this study include the addition of several control groups to evaluate the effect of FMT contrary to the animal's natural behaviour. Using animals with inherent gut microbiota also has great translational value, as it mimics the human gastrointestinal system more closely. The donor material was collected from treatment-naïve patients with MDD, which has not been done previously. Additionally, we assessed the effect of antidepressant treatment on the behavioural effect imposed by FMT, which has not been explored in previous publications.

Declarations

CONFLICT OF INTEREST

Julie Kristine Knudsen declares no conflicts of interest.

Thomas Yssing Michaelsen is affiliated with DNASense as a consultant, but did not receive the data through DNASense, but rather through the first and last authors.

Caspar Bundgaard-Nielsen declares no conflicts of interest.

René Ernst Nielsen has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva A/S and Eli Lilly and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda and Medivir, and has acted as investigator for Janssen-Cilag, Lundbeck, Boehringer, Compass and Sage.

Simon Hjerrild declares no conflicts of interest.

Peter Leutscher declares no conflicts of interest.

Gregers Wegener reported having received lecture/consultancy fees from H. Lundbeck A/S, Servier SA, Astra Zeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd, Pfizer Inc, Shire A/S, Takeda AB, HB Pharma A/S,

Janssen Pharma A/S, Johnson & Johnson Inc, Arla Foods Ingredients P/S., Alkermes Inc, and Mundipharma International Ltd.

Suzette Sørensen declares no conflicts of interest.

AUTHOR CONTRIBUTIONS

JKK, GW and SS designed the study

JKK constructed the draft of the paper

All authors contributed to the data analysis, interpretation of data and finalization of the article

References

1. Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linlokken A, Wilson R, et al. Correlation between the human fecal microbiota and depression. *Neurogastroenterol Motil.* 2014;26(8):1155-62.
2. Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. *Brain, Behavior, and Immunity.* 2015;48:186-94.
3. Zheng P, Zeng B, Zhou C, Liu M, Fang Z, Xu X, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Molecular Psychiatry.* 2016;21(6):786-96.
4. Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Possible association of *Bifidobacterium* and *Lactobacillus* in the gut microbiota of patients with major depressive disorder. *Journal of Affective Disorders.* 2016;202:254-7.
5. Kelly JR, Borre Y, C OB, Patterson E, El Aidy S, Deane J, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res.* 2016;82:109-18.
6. Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, et al. *Prevotella* and *Klebsiella* proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder. *Journal of Affective Disorders.* 2017;207:300-4.
7. Chen JJ, Zheng P, Liu YY, Zhong XG, Wang HY, Guo YJ, et al. Sex differences in gut microbiota in patients with major depressive disorder. *Neuropsychiatr Dis Treat.* 2018;14:647-55.
8. Rong H, Xie XH, Zhao J, Lai WT, Wang MB, Xu D, et al. Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients. *J Psychiatr Res.* 2019;113:90-9.
9. Chung Y-CE, Chen H-C, Chou H-CL, Chen IM, Lee M-S, Chuang L-C, et al. Exploration of microbiota targets for major depressive disorder and mood related traits. *Journal of Psychiatric Research.* 2019;111:74-82.

10. Huang Y, Li Z, Shen Y, Shi X, Wang L, Li G, et al. Possible association of firmicutes in the gut microbiota of patients with major depressive disorder. *Neuropsychiatric Disease and Treatment*. 2018;14:3329-37.
11. Vinberg M, Ottesen NM, Meluken I, Sorensen N, Pedersen O, Kessing LV, et al. Remitted affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota. *Acta psychiatrica Scandinavica*. 2019;139(2):174-84.
12. Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, et al. Age-specific differential changes on gut microbiota composition in patients with major depressive disorder. *Aging (Albany NY)*. 2020;12(3):2764-76.
13. Lai WT, Deng WF, Xu SX, Zhao J, Xu D, Liu YH, et al. Shotgun metagenomics reveals both taxonomic and tryptophan pathway differences of gut microbiota in major depressive disorder patients. *Psychol Med*. 2019:1-12.
14. Liu RT, Rowan-Nash AD, Sheehan AE, Walsh RFL, Sanzari CM, Korry BJ, et al. Reductions in anti-inflammatory gut bacteria are associated with depression in a sample of young adults. *Brain Behav Immun*. 2020;88:308-24.
15. Mason BL, Li Q, Minhajuddin A, Czysz AH, Coughlin LA, Hussain SK, et al. Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia. *J Affect Disord*. 2020;266:394-401.
16. Stevens BR, Roesch L, Thiago P, Russell JT, Pepine CJ, Holbert RC, et al. Depression phenotype identified by using single nucleotide exact amplicon sequence variants of the human gut microbiome. *Mol Psychiatry*. 2020.
17. Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, et al. Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. 2020;7(7):1902862.
18. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat Microbiol*. 2019;4(4):623-32.
19. Knudsen JK, Bundgaard-Nielsen C, Hjerrild S, Nielsen RE, Leutscher P, Sorensen S. Gut microbiota variations in patients diagnosed with major depressive disorder-A systematic review. *Brain Behav*. 2021:e02177.
20. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012;3(1):4-14.
21. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014;157(1):121-41.
22. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell*. 2015;161(2):264-76.
23. Browning KN, Travagli RA. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. *Compr Physiol*. 2014;4(4):1339-68.
24. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Annals of Gastroenterology*. 2015;28(2):203-9.

25. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. *Ann Gastroenterol*. 2015;28(2):203-9.
26. Averina OV, Zorkina YA, Yunes RA, Kovtun AS, Ushakova VM, Morozova AY, et al. Bacterial Metabolites of Human Gut Microbiota Correlating with Depression. *Int J Mol Sci*. 2020;21(23).
27. Rudzki L, Ostrowska L, Pawlak D, Malus A, Pawlak K, Waszkiewicz N, et al. Probiotic *Lactobacillus Plantarum* 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. *Psychoneuroendocrinology*. 2019;100:213-22.
28. Chahwan B, Kwan S, Isik A, van Hemert S, Burke C, Roberts L. Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms. *Journal of Affective Disorders*. 2019;253:317-26.
29. Yu M, Jia H, Zhou C, Yang Y, Zhao Y, Yang M, et al. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics. *J Pharm Biomed Anal*. 2017;138:231-9.
30. Chen Z, Li J, Gui S, Zhou C, Chen J, Yang C, et al. Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. *Neuroreport*. 2018;29(5):417-25.
31. Jianguo L, Xueyang J, Cui W, Changxin W, Xuemei Q. Altered gut metabolome contributes to depression-like behaviors in rats exposed to chronic unpredictable mild stress. *Translational psychiatry*. 2019;9(1):40.
32. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell*. 2013;155(7):1451-63.
33. Sharon G, Cruz NJ, Kang DW, Gandal MJ, Wang B, Kim YM, et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. *Cell*. 2019;177(6):1600-18 e17.
34. Ohlsson L, Gustafsson A, Lavant E, Suneson K, Brundin L, Westrin A, et al. Leaky gut biomarkers in depression and suicidal behavior. *Acta psychiatrica Scandinavica*. 2019;139(2):185-93.
35. Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut microbiota's effect on mental health: The gut-brain axis. *Clin Pract*. 2017;7(4):987.
36. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol*. 2016;16(6):341-52.
37. Luo Y, Zeng B, Zeng L, Du X, Li B, Huo R, et al. Gut microbiota regulates mouse behaviors through glucocorticoid receptor pathway genes in the hippocampus. *Translational psychiatry*. 2018;8(1):187.
38. Liu S, Guo R, Liu F, Yuan Q, Yu Y, Ren F. Gut Microbiota Regulates Depression-Like Behavior in Rats Through the Neuroendocrine-Immune-Mitochondrial Pathway. *Neuropsychiatr Dis Treat*. 2020;16:859-69.
39. Overstreet DH. The Flinders sensitive line rats: a genetic animal model of depression. *Neurosci Biobehav Rev*. 1993;17(1):51-68.

40. Overstreet DH, Friedman E, Mathe AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. *Neurosci Biobehav Rev.* 2005;29(4-5):739-59.
41. Abildgaard A, Solskov L, Volke V, Harvey BH, Lund S, Wegener G. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. *Psychoneuroendocrinology.* 2011;36(5):623-33.
42. Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. *PLoS Biol.* 2020;18(7):e3000411.
43. Tannenbaum J, Bennett BT. Russell and Burch's 3Rs then and now: the need for clarity in definition and purpose. *J Am Assoc Lab Anim Sci.* 2015;54(2):120-32.
44. Smalheiser NR, Graetz EE, Yu Z, Wang J. Effect size, sample size and power of forced swim test assays in mice: Guidelines for investigators to optimize reproducibility. *PLoS One.* 2021;16(2):e0243668.
45. Yankelevitch-Yahav R, Franko M, Huly A, Doron R. The forced swim test as a model of depressive-like behavior. *J Vis Exp.* 2015(97).
46. Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. *Nat Protoc.* 2012;7(6):1009-14.
47. Overstreet DH, Wegener G. The flinders sensitive line rat model of depression—25 years and still producing. *Pharmacol Rev.* 2013;65(1):143-55.
48. Overstreet DH, Keeney A, Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. *Eur J Pharmacol.* 2004;492(2-3):195-201.
49. Pucilowski O, Overstreet DH. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. *Brain research bulletin.* 1993;32(5):471-5.
50. Melis V, Usach I, Peris JE. Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies. *J Sep Sci.* 2012;35(23):3302-7.
51. Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut.* 2017;66(4):569-80.
52. Bailey KR, Crawley JN. Anxiety-Related Behaviors in Mice. In: Buccafusco JJ, editor. *Methods of Behavior Analysis in Neuroscience.* Frontiers in Neuroscience. 2nd ed. Boca Raton (FL)2009.
53. Seibenhener ML, Wooten MC. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. *J Vis Exp.* 2015(96):e52434.
54. Bundgaard-Nielsen C, Hagstrom S, Sorensen S. Interpersonal Variations in Gut Microbiota Profiles Supersedes the Effects of Differing Fecal Storage Conditions. *Scientific Reports.* 2018;8.
55. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. *BMC Genomics.* 2012;13:341.

56. Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, et al. Improved Bacterial 16S rRNA Gene (V4 and V4-5) and Fungal Internal Transcribed Spacer Marker Gene Primers for Microbial Community Surveys. *mSystems*. 2016;1(1).
57. Parada AE, Needham DM, Fuhrman JA. Every base matters: assessing small subunit rRNA primers for marine microbiomes with mock communities, time series and global field samples. *Environmental microbiology*. 2016;18(5):1403-14.
58. Albertsen M, Karst SM, Ziegler AS, Kirkegaard RH, Nielsen PH. Back to Basics–The Influence of DNA Extraction and Primer Choice on Phylogenetic Analysis of Activated Sludge Communities. *PLoS One*. 2015;10(7):e0132783.
59. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014;30(15):2114-20.
60. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. *Bioinformatics*. 2011;27(21):2957-63.
61. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*. 2010;26(19):2460-1.
62. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7(5):335-6.
63. McIlroy SJ, Kirkegaard RH, McIlroy B, Nierychlo M, Kristensen JM, Karst SM, et al. MiDAS 2.0: an ecosystem-specific taxonomy and online database for the organisms of wastewater treatment systems expanded for anaerobic digester groups. *Database (Oxford)*. 2017;2017(1).
64. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
65. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J R Stat Soc B*. 1995;57(1):289-300.
66. Chahwan B, Kwan S, Isik A, van Hemert S, Burke C, Roberts L. Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms. *J Affect Disord*. 2019;253:317-26.
67. El Aidy S, Ramsteijn AS, Dini-Andreote F, van Eijk R, Houwing DJ, Salles JF, et al. Serotonin Transporter Genotype Modulates the Gut Microbiota Composition in Young Rats, an Effect Augmented by Early Life Stress. *Frontiers in cellular neuroscience*. 2017;11:222.
68. Millstein RA, Holmes A. Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. *Neurosci Biobehav Rev*. 2007;31(1):3-17.
69. Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. *Brain Behav Immun*. 2011;25(3):397-407.
70. Anand S, Kaur H, Mande SS. Comparative In silico Analysis of Butyrate Production Pathways in Gut Commensals and Pathogens. *Front Microbiol*. 2016;7:1945.

71. Skonieczna-zydecka K, Grochans E, Maciejewska D, Szkup M, Schneider-Matyka D, Jurczak A, et al. Faecal short chain fatty acids profile is changed in Polish depressive women. *Nutrients*. 2018;10(12):1939.

Figures

Figure 1

Behavioural analysis of the forced swim test of FSL and FRL rats. Total immobility time (sec) (A, C) and total struggling time (sec) (B, D) of rats from each group of FRL (A, B) or FSL (C, D) rats based on recordings of the first 5 minutes. P-values were included in the figure if they were below 0.2. Grey lines represent cohoused animals in the FRL group. The red dot represents the rat that was removed from the analysis as mentioned in the Methods section. FMT-MDD: Faecal microbiota transplantation from patients with MDD into rats. FMT-Healthy: Faecal microbiota transplantation from healthy individuals into rats. FMT-MDD-Ser: Faecal microbiota transplantation from patients with MDD into rats combined with treatment with sertraline. CON-Auto: Rats receiving auto-transplantations. CON-H2O: Rats receiving demineralised water.

Figure 2

Stacked bar plots of relative changes in gut microbiota composition of FRL rats. Each bar represents all the OTUs observed across samples from one rat. OTUs in blue were detected in both pre-and post-FMT samples, while OTUs in purple were novel in the rat and not detected in the donor material. The green OTUs were common in both rats and humans, while the red percentage was unique to the human donor material only. FMT-MDD: Faecal microbiota transplantation from patients with MDD into rats. FMT-

Healthy: Faecal microbiota transplantation from healthy individuals into rats. FMT-MDD-Ser: Faecal microbiota transplantation from patients with MDD into rats combined with treatment with sertraline.

Figure 3

MA plot presenting the fold change in OTU expression between pre-FMT and post-FMT samples collected from FRL rats. (A) OTU expression in rats receiving faecal microbiota transplantation (FMT) from patients with MDD (FMT-MDD) compared to rats receiving from healthy individuals (FMT-Healthy). Of all the OTUs, seventeen were elevated in FMT-MDD samples, while eight were depleted compared to FMT-Healthy samples. (B) The twenty-five OTUs significantly different between FMT-MDD animals and FMT-Healthy animals. Five of these OTUs, marked by “X”, could be traced to the human donor material. The fold change is expressed as the change in relative abundance of bacteria in the FMT-MDD group compared to the FMT-Healthy group.

Figure 4

Relative mRNA expression of tight junction protein-encoding genes in the caecum of FRL rats. A) Relative gene expression of *ocln* in rats. B) Relative gene expression of *cln3* in rats. Gene expression was normalized against gene expression of *gapdh* using the $\Delta\Delta Ct$ method. FMT-MDD: Faecal microbiota transplantation from patients with MDD into rats. FMT-Healthy: Faecal microbiota transplantation from healthy individuals into rats. FMT-MDD-Ser: Faecal microbiota transplantation from patients with MDD into rats combined with treatment with sertraline. CON-Auto: Rats receiving auto-transplantations. CON-H2O: Rats receiving demineralised water.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [JKKFMTstudy1V3.7SupplementaryFigure1.jpg](#)
- [JKKFMTstudy1V3.7SupplementaryFigure2.jpg](#)
- [JKKFMTstudy1V3.7SupplementaryFigure3.jpg](#)
- [JKKFMTstudy1V3.7SupplementaryFigureLegends.docx](#)